Insulet Corporation
$ 201.47
-0.51%
16 Apr - close price
- Market Cap 14,182,652,000 USD
- Current Price $ 201.47
- High / Low $ 205.30 / 200.54
- Stock P/E 57.73
- Book Value 21.53
- EPS 3.49
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 0.18 %
- 52 Week High 354.88
- 52 Week Low 194.61
About
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts.
Analyst Target Price
$333.30
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-18 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-20 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-22 | 2023-11-02 | 2023-08-08 | 2023-05-04 |
| Reported EPS | 1.44 | 1.24 | 1.17 | 1.02 | 1.15 | 0.9 | 0.55 | 0.73 | 1.4 | 0.71 | 0.38 | 0.23 |
| Estimated EPS | 1.46 | 1.14 | 0.92 | 0.79 | 1.021 | 0.76 | 0.56 | 0.39 | 0.66 | 0.4 | 0.26 | 0.11 |
| Surprise | -0.02 | 0.1 | 0.25 | 0.23 | 0.129 | 0.14 | -0.01 | 0.34 | 0.74 | 0.31 | 0.12 | 0.12 |
| Surprise Percentage | -1.3699% | 8.7719% | 27.1739% | 29.1139% | 12.6347% | 18.4211% | -1.7857% | 87.1795% | 112.1212% | 77.5% | 46.1538% | 109.0909% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.14 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PODD
2026-04-17 10:08:21
Insulet Corp. (NASDAQ: PODD) recently hit a new 52-week low of USD 197.63, reflecting a 20% decline in its stock price over the past year. Despite healthy net sales growth of 24.53% annually, the company faces challenges with a 24.56% decline in net profit and a high price-to-earnings ratio of 46.00, indicating investor concerns about its financial performance.
2026-04-16 12:39:31
Levi & Korsinsky, LLP has announced an investor alert regarding Phreesia, Inc. (NYSE: PHR) following a significant drop in its stock price. The investigation stems from Phreesia cutting its FY 2027 revenue guidance from an initial $545-$559 million to $510-$520 million, causing a 29% loss for investors. The firm is encouraging affected shareholders to come forward to discuss potential securities fraud claims.
2026-04-16 10:00:00
Pomerantz LLP has filed a class action lawsuit against Vital Farms, Inc. (VITL) following the company's annual report for 2025, which showed a revenue miss and lower-than-expected earnings per share. The company attributed these results to "temporary disruptions" caused by the implementation of an ERP system. Investors who purchased Vital Farms securities during the class period have until May 26, 2026, to seek appointment as Lead Plaintiff.
2026-04-16 09:08:17
Insulet (NasdaqGS:PODD) has issued a voluntary medical device correction for specific batches of its Omnipod 5 system in the U.S. due to a manufacturing flaw in the internal insulin delivery tubing, posing potential health risks. This correction highlights execution risks for the company's key product, with shares currently trading significantly below analyst targets and showing weak short-term momentum. The company is updating quality control processes and the market will be watching how Insulet manages this issue with patients, clinicians, and regulators.
2026-04-16 09:00:00
Levi & Korsinsky, LLP has issued an investor alert regarding Insulet Corp. (NASDAQ: PODD) after executives allegedly misled investors about the safety and reliability of its Omnipod 5 system. Just two weeks after the CEO praised the product on an earnings call, the company disclosed a voluntary recall due to an insulin-leakage defect linked to serious adverse events, causing PODD shares to fall. Shareholders who suffered losses are encouraged to seek legal counsel to potentially lead a class action lawsuit.
2026-04-15 12:59:36
Levi & Korsinsky, LLP is investigating Insulet Corp. (NASDAQ: PODD) for potential securities fraud after the company disclosed a voluntary medical device correction for its Omnipod 5 insulin pods due to a design defect causing insulin leakage, which has been linked to eighteen serious adverse events. This disclosure caused Insulet shares to drop by approximately 6.9%. The investigation will focus on whether Insulet executives concealed knowledge of this defect prior to the public announcement on March 12, 2026.
